Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
250
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Revised forecast
Fiscal year ending March 2026 · Full yearNet Sales—→10,350million
—
Operating profit—→300million
—
Ordinary income—→360million
—
Profit attributable to owners of the parent—→250million
—
Net income per share—→30.93yen and sen
—
The bar length represents the relative magnitude of change, based on the item that changed the most in this document.
Reason for the revision
2025年5月14日時点では米国関税措置等の未確定要素により通期連結業績予想の算出が困難だったが、影響について一定程度の見通しがついたため公表。ファインケミカル事業の半導体・医薬・ヨウ素関連製品の販売増加、難燃剤事業の収益状況改善を見込む。
Previous-period results売上高9,304百万円、営業利益△342百万円、経常利益△275百万円、親会社株主に帰属する当期純利益△895百万円、１株当たり当期純利益△110.77円
Consolidated / non-consolidatedConsolidated
| Item | Details |
|---|---|
| Net Sales | Not disclosed → ¥10,350 million |
| Operating profit | Not disclosed → ¥300 million |
| Ordinary income | Not disclosed → ¥360 million |
| Profit attributable to owners of the parent | Not disclosed → ¥250 million |
| Net income per share | Not disclosed → 30.93 yen and sen |
| Fiscal Period Covered | Fiscal year ending March 2026 |
| Period Covered | Full year |
| Previous-period results | 売上高9,304百万円、営業利益△342百万円、経常利益△275百万円、親会社株主に帰属する当期純利益△895百万円、１株当たり当期純利益△110.77円 |
| Reason for the revision | 2025年5月14日時点では米国関税措置等の未確定要素により通期連結業績予想の算出が困難だったが、影響について一定程度の見通しがついたため公表。ファインケミカル事業の半導体・医薬・ヨウ素関連製品の販売増加、難燃剤事業の収益状況改善を見込む。 |
| Consolidated / non-consolidated | Consolidated |
Items this document does not state (3)
Publication date of previous forecastDetails and amount of extraordinary lossDividend forecast revision
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.2025年5月14日時点では米国関税措置等の未確定要素により合理的な予想の算出が困難だったものの、影響について一定程度の見通しがついたため公表しました。ファインケミカル事業では半導体分野、医薬分野、ヨウ素関連製品を中心に販売増加を見込み、難燃剤事業では中国経済減速に伴う市況低迷が続く可能性が高い一方、収益状況の改善を見込んでいます。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.